Asset profile
Levodopa Cyclops
Combination
Evidence outlook · lead readout
NCT06037590 · Parkinson, Parkinson Disease, Parkinson's Disease and Parkinsonism
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06037590: Participants were randomly assigned to the order in which they received each treatment, and the comparison was against an already-approved inhaled levodopa product. However, nobody involved was blinded to which product was being given, only 26 people took part, and the trial measured blood drug levels rather than a symptom or functional outcome. No results are posted yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.